Journal Article

Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type

Shannon L Kanis, Alison de Lima-Karagiannis, Cokkie van der Ent, Dimitris Rizopoulos and C Janneke van der Woude

in Journal of Crohn's and Colitis

Published on behalf of European Crohn's and Colitis Organisation

Volume 12, issue 8, pages 939-947
Published in print July 2018 | ISSN: 1873-9946
Published online May 2018 | e-ISSN: 1876-4479 | DOI: https://dx.doi.org/10.1093/ecco-jcc/jjy058
Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type

More Like This

Show all results sharing these subjects:

  • Gastroenterology
  • Paediatrics
  • Economics of Health
  • Health, Illness, and Medicine

GO

Show Summary Details

Preview

Abstract

Background and Aims

Pregnancy guidelines for women with inflammatory bowel disease [IBD] provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit foetal exposure. Although infliximab [IFX] leads to higher anti-TNF concentrations in cord blood than adalimumab [ADA], the recommendations are similar. We aimed to demonstrate the effect of anti-TNF cessation during pregnancy on foetal exposure, for IFX and ADA separately.

Methods

We conducted a prospective single-center cohort study. Women with IBD, using IFX or ADA, were followed-up during pregnancy. In case of sustained disease remission, anti-TNF was stopped in the third trimester. At the birth, the anti-TNF concentration was measured in the cord blood. A linear regression model was developed to demonstrate anti-TNF concentration in cord blood at birth. In addition, outcomes such as disease activity, pregnancy outcomes and 1-year health outcomes of infants were collected.

Results

We included 131 pregnancies that resulted in a live birth [73 IFX, 58 ADA]. At birth, 94 cord blood samples were obtained [52 IFX, 42 ADA], showing significantly higher levels of IFX than ADA [p < 0.0001]. Anti-TNF type and stop week were used in the linear regression model. During the third trimester, IFX transportation over the placenta increased exponentially; however, ADA transportation was limited and increased in a linear fashion. Overall, health outcomes were comparable.

Conclusions

Our linear regression model shows that ADA may be continued longer during pregnancy, because transportation over the placenta is lower than for IFX. This may reduce relapse risk of the mother, without increasing foetal anti-TNF exposure.

Keywords: Infliximab; adalimumab; pregnancy

Journal Article.  6120 words.  Illustrated.

Subjects: Gastroenterology ; Paediatrics ; Economics of Health ; Health, Illness, and Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.